With so many shares to choose from on the Australian share market, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.
Three top ASX shares that leading brokers have named as buys this week are listed below. Here's why they are bullish on them:
Image source: Getty Images
CSL Ltd (ASX: CSL)
According to a note out of Citi, its analysts have retained their buy rating and $225.00 price target on this biotherapeutics company's shares. The broker highlights that CSL shares were sold off in 2025 amid concerns over margins, influenza vaccine demand, immunoglobulins growth, and Seqirus uncertainty. It believes there is scope for a recovery in 2026 even if its net profits don't grow in the double-digits. Citi thinks that rebuilding investor confidence will be more important than beating earnings estimates. The CSL share price is trading at $183.18 on Tuesday afternoon.
Life360 Inc (ASX: 360)
A note out of Bell Potter reveals that its analysts have retained their buy rating on this location technology company's shares with a reduced price target of $45.00. Bell Potter was impressed with Life360's performance in the fourth quarter and FY 2025. It highlights that its trading update was ahead of both guidance and its forecasts. This includes monthly active users rising to 95.8 million (vs Bell Potter's estimate of 93.5 million), paying circles of 2.83 million (vs Bell Potter's estimate of 2.8 million), and adjusted EBITDA of between US$87 million and US$92 million (vs Bell Potter's estimate of US$86 million). And with management guiding to monthly active user growth of 20% in 2026, the broker is feeling very positive about its outlook. And while its valuation has been reduced to reflect a re-rating of tech valuations, it still sees plenty of upside for investors. The Life360 share price is fetching $31.03 at the time of writing.
Pro Medicus Ltd (ASX: PME)
Analysts at Macquarie have upgraded this health imaging technology company's shares to an outperform rating with a trimmed price target of $291.30. According to the note, the broker made the move on valuation grounds following significant share price weakness. In addition, it has received industry feedback that indicates that Pro Medicus is likely to continue winning market share over the near term. It also believes that its AI offering will strengthen the Visage offering and cement its leadership position. The Pro Medicus share price is trading at $188.00 this afternoon.
